09/02/20 00:40:30 C2HgvFA40
VX-750の開発メーカ Vertexの プレスリリースより引用
URLﾘﾝｸ(investors.vrtx.com)
CAMBRIDGE, Mass., Mar 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals
Incorporated (Nasdaq: VRTX) and Tibotec today announced that patient
screening has begun in the ADVANCE study, a pivotal Phase 3 clinical
study with the hepatitis C virus (HCV) protease inhibitor telaprevir
in combination therapy for treatment-naive patients with chronic HCV
infection. Telaprevir is the most advanced HCV protease inhibitor in
clinical development targeting treatment of hepatitis C.
（中略）
The ADVANCE Study
The ADVANCE study (A New Direction in HCV Care: A Study of Treatment-
Naive Hepatitis C Patients with telaprevir) will be conducted at more
than 100 centers in the U.S., E.U. and certain other countries. Patient
ecruitment is being initiated in the U.S., while sites in other countries
will start recruitment as national Clinical Trial Applications (CTAs)
for each country are approved. The study arms will include:
-- 24 weeks of therapy, with telaprevir dosed at 750 mg every eight
hours (q8h) for 12 weeks in combination with standard doses of
pegylated interferon alfa-2a (peg-IFN) and ribavirin (RBV) for
12 weeks, then continuing for another 12 weeks with peg-IFN and
RBV alone;
（以下略）
VX-750の Phase3 の昨年開始された世界規模のPhase3の臨床試験は
alfa-2a (peg-IFN) ペガシス ＋ ribavirin (RBV) リバビリン
との３者併用ですよ。>>713 は typo （スペルミス）ではないの？